Answers are grounded in this paper and cite their sources.
In vitro study demonstrates dual anticancer and antimicrobial potency across cancer cells and resistant bacteria, suggesting therapeutic potential for targeted dual-action conjugates.
A series of triphenylphosphonium (TPP) conjugates of 1,2,3-triazolyl analogues of pyrimidine nucleosides was synthesized. In these compounds a TPP cation was attached via a decamethylene linker to the atom N-3 of the nucleic base (uracil, thymine) or its analog (6-methyluracil), and the N-acetyl-β-D-glucosamine residue with protected (or unprotected) hydroxyl groups was attached via a 1,2,3-triazolylmethyl or 1,2,3-triazolylbutyl linker to the atom N-1 of the listed pyrimidine derivatives. All synthesized TPP-conjugates caused the death of MCF-7 cancer cells within the range IC50 = 1.9–27 µM and PC-3 cancer cells within the range IC50 = 2.6–19.4 µM. Bacteriostatic and bactericidal activity against Gram-positive bacteria Staphylococcus aureus, Bacillus cereus, and methicillin-resistant strains of S. aureus MRSA-1 and MRSA-2 was detected for several TPP-conjugates within the concentration range (MIC and MBC) from 7.8 to 15.6 µM.
No takes yet. Share an insight, caveat, or question.
Safargalieva et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: